ORC Expert Advisory Services ORC International

  home    |    find an expert    |    request an expert    |    join our network    |    about us     expert login  
Expert Consulting and Expert Witness Services
  search tips 
Share this page:  Send to LinkedIn Send to Facebook Tweet This Email Print

 Expert  723081

Expert in Virology, Anti-infectives, Gene Therapy, Bioterrorism Research

Available for your Consulting and Expert Witness Needs

Hawaii (HI)
Education Work History Career AccomplishmentsPublicationsConsulting Services Expert Witness

Summary of Expertise:

Listed with other top experts in: 

He has extensive experience in the development and use of viral vectors for gene transfer and in particular has worked with both adenovirus and AAV vector delivery systems. His work with adenovirus vectors included some of the earliest research focused on the development of cell targeted vectors through genetic manipulation of the adenovirus fiber protein. This work resulted in two issued US patents and several publications in peer-reviewed journals. The concept of retargeting adenoviruses using the fiber modification approach is in widespread use today and is of particular importance in oncology applications where fiber modified adenovirus vectors are being evaluated in clinical trials.



He headed a research team at Bayer that succeeded in identifying Inter-Cellular Adhesion Molecule-1 (ICAM-1) as the receptor for human rhinoviruses, the primary cause of the common cold. This work led to important new insights into the mechanism of rhinovirus infection and the development of a soluble receptor decoy that was one of the first antiviral entry inhibitor drugs to be tested in humans. His recent work in antiviral research has focused on efforts to identify inhibitors of dengue virus entry based on the X-ray crystal structure of the viral envelope protein.

antiviral agent


common cold virus

The scale up of manufacturing technology for viral vectors used in gene therapy and vaccine applications continues to present significant technical and regulatory challenges, due to the complexity of these biological products.He has worked with both adenovirus and AAV vectors and oversaw the work of a development team that made several advances in the scale up of AAV vectors for human gene transfer studies. These included the development of a partially automated cell culture system allowing for consistent scalable production of AAV using a plasmid DNA based transfection system and the use of column chromatography based purification methods.

biological virus production

He has over a decade of experience in the development of gene transfer approaches to treat disease, and has published extensively in this field. He joined Genetic Therapy Inc in 1992 as Director of Molecular and Cell Biology and headed research programs in adenovirus vector development, non-viral gene transfer, hemophilia and cardiovascular disease. Following the acquisition of GTI by Novartis in 1995, He was promoted to Vice-President of Research, assuming responsibility for the research programs in respiratory disease and oncology, in addition to the hemophilia and cardiovascular programs. He also established and managed several collaborations within the Novartis research organization as well as with external academic research groups. From 1999 to 2003 he headed R & D at Avigen Inc, a biotechnology company that was focused exclusively on the use of adeno-associated virus (AAV) as a gene delivery vector for the treatment of inherited and acquired diseases. Under his leadership Avigen successfully completed two Phase I clinical trails for the treatment of hemophilia B using AAV vectors and initiated a clinical trial for Parkinson's disease. He recruited and assembled a process development team that was able to scale up the production and purification process for AAV vectors as well as developing new and improved analytical methods for QC testing of vector product used in human clinical studies


gene therapy

He has over 10 years of experience in the development of gene therapy approaches to the treatment of hemophilia A and B. At Genetic Therapy Inc. his research included some of the first studies to show the potential for gene transfer approaches to correct hemophilia in canine models of this genetic disease. Subsequently, at Avigen Inc., he oversaw a research team that collaborated with investigators at Children's Hospital of Philadelphia and Stanford University in the first human clinical studies to evaluate the use of AAV vectors for treatment of hemophilia B


Show Secondary and Basic Areas of Expertise
Expert may consult nationally and internationally, and is also local to the following cities: Honolulu, Hawaii.

Year   Degree   Subject   Institution   Honors
1981   PhD   Biochemistry   University of London  
1977   BS   Molecular Biology   University of Edinburgh   First Class Honors

Work History:
Years   Employer   Department   Title   Responsibilities

2003 to 2005


Hawaii Biotech Inc


Discovery Research


Vice President


He was responsible for leading research programs in small molecule drug discovery, focusing on infectious disease and bioterrorism targets, and was PI on several NIH grants and Dept. of Defense contracts

1999 to 2003


Avigen Inc



Vice President, Research and Development


He was responsible for preclinical research and development, leading a group of approximately 50 scientists dedicated to the development of adeno-associated virus (AAV) based human therapeutic products for inherited and aquired disease including hemophilia and Parkinson's disease

1997 to 1999




Genetic Therapy Inc


Vice President, Research


He was responsible for scientific leadership and management of 80 researchers developing gene delivery based therapies, and was a member of the Novartis Research Management Board.

1992 to 1997


Genetic Therapy Inc



Laboratory Director


He established and led a research team comprising up to 40 scientists conducting research in gene therapy for inherited and aquired diseases including hemophilia, cardiovascular disease and organ transplantation rejection. He led vector development research in targeted gene delivery that resulted in issued US patents for this technology

1985 to 1992




Molecular Therapeutics Inc


Principal Staff Scientist


He planned, initiated and built an anti-viral research discovery program which discovered the major human rhinovirus receptor (ICAM-1). He headed group which designed, produced and tested soluble receptor molecules based on ICAM-1, developed mammalian production cell lines and advanced a candidate molecule through preclinical testing in primates

Career Accomplishments:

Member of the American Society for Gene Therapy Member of the National Hemophilia Foundation

Professional Appointments

Member of External Scientific Advisory Board, Center for Transgene Technology and Gene Therapy, University of Leuven, May 1997


He was a recipient of a Science and Engineering Research Council postdoctoral fellowship award, and received the Miles Corporate Science Award in 1990 for research leading to the discovery of the human rhinovirus receptor

Publications and Patents Summary

He has over 40 publications in peer reviewed journals and 17 issued US patents

Selected Publications and Publishers  
 - Nature Genetics  
 - Journal of Virology  
 - Proceedings of the National Academy of Sciences  
 - Cell  

Government Experience:
Years   Agency   Role   Description
2004 to 2005   Dept of Defense   Principal Investigator   He served as Principal Investigator for a contract research project investigating small molecule inhibitors of anthrax lethal toxin protease
2004 to 2005   NIH   Principal Investigator   He served as Principal Investigator for a Phase II SBIR grant from NIAID investiagting anthrax lethal toxin ihhibitors

Consulting Services:
Selected Consulting Examples:
  • He was a member of the External Scientific Advisory Board of the Center for Transgene Technology and Gene Therapy in Leuven, Belgium which conducted a two day site visit and scientific review of the research programs
  • Provided scientific advice and project evaluation to a Contract Research Organization in the area of gene therapy, assisting the CRO in preparing recommendations for a product development plan to a client organization. This assignment included participation in client meetings and preparation of reports.
  • Currently advising a client in the area of biodefense research, providing strategic and technical input to the formulation of the business plan and R & D direction
Click the green button above to contact Expert for a free initial screening call regarding your expert consulting needs.  Expert is available for consulting to corporate, legal and government clients.  Remember, your initial screening call to speak with Expert is free.

Expert Witness:
Click the green button above to contact Expert for a free initial screening call regarding expert testimony, litigation consulting and support, forensic services, or any related expert witness services.  A few litigation needs include product liability, personal injury, economic loss, intellectual property (patent, trademark, trade secret, copyright), and insurance matters.  Remember, your initial screening call to speak with Expert is free.

International Experience:
Years   Country / Region   Summary
1977 to 1981   United Kingdom   Graduate research leading to PhD degree at the University of London
1997 to 1997   Belgium   Member of External Scientific Advisory Board, CTTGT, Leuven, Belgium
1985 to 1992   Germany   He was employed by Molecular Therapeutics inc., a wholly owned subsidiary of Bayer AG. Position involved reguar travel to Germany to particpate in scientific planning and strategy meetings , and management of R&D collaborations
1995 to 1999   Switzerland   He was Vice President of Research for Genetic Therapy Inc. a subsidiary of Novartis. In this capacity Expert was a member of the Novartis Research Management Board and participated in oversight and review of pharmaceutical research programs, including an annual review of the entire pharma research portfolio

Additional Skills and Services:

He was a lecturer in the Gene Therapy Course offfered in the Johns Hopkins University Masters in Biotechnology program from 1994 to 1996. He has given numerous scientific presentations at academic institutions and national and international scientific meetings. He organized and chaired two Corporate Symposia that were part of the scientific program of the American Society of Gene Therapy in 2001 and 2002

Supplier and Vendor Location and Selection

He has selected CROs for the conduct of GLP toxicology studies that were included in IND submissions to the FDA

Other Skills and Services

He has written and submitted successful grant applications to the NIH including recent SBIR grants in the areas of bioterrorism preparedness and emerging infectious disease


Need the right expert?  We can help!

home       find an expert       request an expert       join our network       about us

Intota is now ORC Expert Advisory Services